Skip to main content

Table 2 Distribution of treatment regimens

From: Efficacy and safety of intravenous daratumumab-based treatments for AL amyloidosis: a systematic review and meta-analysis

Treatment regimens

n of patients

Rate (%)

Dara ± dex

665

66.7

DVd

108

10.8

DRd

71

7.1

DCd

4

0.4

Mixed Daratumumab-based treatments*

149

15.0

  1. Dara ± dex  Daratumumab ± Dexamethasone, DVd  Daratumumab + Bortezomib + Dexamethasone, DRd  Daratumumab + Lenalidomide + Dexamethasone, DCd  Daratumumab + Cyclophosphamide + Dexamethasone
  2. *Mixed Daratumumab-based treatments indicate there were more than one kind of daratumumab-based treatment in the study (daratumumab was combined with dexamethasone, bortezomib, lenalidomide, pomalidomide, cyclophosphamide, ixazomid or carfilzomib)
Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us